Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320768 | 0.95 | ACHE (0.48) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL5350898 | 0.94 | ACHE (0.47) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL5358672 | 0.94 | ACHE (0.47) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL1894406 | 0.85 | NCF1 (0.46) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL15923395 | 0.81 | KDM4E (0.55) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL5455544 | 0.80 | ALDH1A1 (0.46) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL5800686 | 0.80 | ACHE (0.46) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL6104934 | 0.78 | ALDH1A1 (0.47) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL1490764 | 0.77 | SMN1; SMN2 (0.43) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL2368949 | 0.76 | KDM4E (0.46) | ACHEALDH1A1HSD17B10KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288550-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-6949649-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-20050209267-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-6921826-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1541572-A1 | Thioether substituted imidazoquinolines | 3M Innovative Properties Company (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1341791-B1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1451191-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-27 | — | — | US | disclosed |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-6667312-B2 | Useful as immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-23 | — | — | US | disclosed |
| US-6664264-B2 | Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| WO-2003050121-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209267-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | ACHE 4781/4885ALDH1A1 2256/4885HSD17B10 3698/4885 |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | ACHE 4781/4885ALDH1A1 2256/4885HSD17B10 3698/4885 |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | ACHE 4781/4885ALDH1A1 2256/4885HSD17B10 3698/4885 |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | ACHE 4781/4885ALDH1A1 2256/4885HSD17B10 3698/4885 |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | ACHE 4781/4885ALDH1A1 2256/4885HSD17B10 3698/4885 |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | ACHE 4781/4885ALDH1A1 2256/4885HSD17B10 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.